Evidence map›Paper›PMID 38730270›Full record

ArticleLeukemia2024

Genomic landscape of CCUS compared to MDS and its implications on risk prediction.

Sandra Huber, Constance Baer, Stephan Hutter, Natalie Wossidlo, Gregor Hoermann, Christian Pohlkamp, Wencke Walter, Manja Meggendorfer, Wolfgang Kern, Torsten Haferlach and 1 more

Abstract readLetterComparative Study
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sandra HuberMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.
Constance BaerMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.ORCID 0000-0002-8571-1551
Stephan HutterMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.ORCID 0000-0003-2432-8898
Natalie WossidloMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.
Gregor HoermannMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.ORCID 0000-0002-7374-4380
Christian PohlkampMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.
Wencke WalterMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.ORCID 0000-0002-5083-9838
Manja MeggendorferMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.ORCID 0000-0002-9038-3265
Wolfgang KernMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.ORCID 0000-0002-6452-2874
Torsten HaferlachMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.ORCID 0000-0003-0196-2837
Claudia HaferlachMLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany. claudia.haferlach@mll.com.ORCID 0000-0002-6333-5049

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

GenomicsMyelodysplastic SyndromesAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationPrognosisRisk Assessment

Identifiers

PMID38730270
PMCPMC11216976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.